889 related articles for article (PubMed ID: 19808194)
1. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
[TBL] [Abstract][Full Text] [Related]
2. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
[TBL] [Abstract][Full Text] [Related]
5. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
[TBL] [Abstract][Full Text] [Related]
6. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
7. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.
Rusch VW; Albain KS; Crowley JJ; Rice TW; Lonchyna V; McKenna R; Livingston RB; Griffin BR; Benfield JR
J Thorac Cardiovasc Surg; 1993 Jan; 105(1):97-104; discussion 104-6. PubMed ID: 8380477
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
Burkes RL; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Jones D; Farooq S; McGlaughlin J; Ginsberg RJ
Lung Cancer; 2005 Jan; 47(1):103-9. PubMed ID: 15603860
[TBL] [Abstract][Full Text] [Related]
9. Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
Weitberg AB; Liu L; Yashar J; Glicksman AS
J Exp Clin Cancer Res; 2001 Sep; 20(3):335-40. PubMed ID: 11718211
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
[TBL] [Abstract][Full Text] [Related]
11. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
Uy KL; Darling G; Xu W; Yi QL; De Perrot M; Pierre AF; Waddell TK; Johnston MR; Bezjak A; Shepherd FA; Keshavjee S
J Thorac Cardiovasc Surg; 2007 Jul; 134(1):188-93. PubMed ID: 17599507
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.
Hehr T; Friedel G; Steger V; Spengler W; Eschmann SM; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1376-81. PubMed ID: 19864078
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer.
Fischer JR; Manegold C; Bülzebruck H; Vogt-Moykopf I; Drings P
Semin Oncol; 1994 Jun; 21(3 Suppl 4):20-7. PubMed ID: 7516094
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.
Langer CJ; Curran WJ; Keller SM; Catalano RB; Litwin S; Blankstein KB; Haas N; Campli SN; Comis RL
Cancer J Sci Am; 1996; 2(2):99-105. PubMed ID: 9166507
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
18. [Effect of preoperative chemotherapy for bulky N2 non-small-cell lung cancer].
Togashi K; Sugawara M; Miyamura H; Sato Y; Tanabe Y; Kourakata H; Saito H; Sato K
Kyobu Geka; 1999 Oct; 52(11):915-9. PubMed ID: 10513156
[TBL] [Abstract][Full Text] [Related]
19. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).
Eberhardt WE; Gauler TC; Lepechoux C; Stamatis G; Bildat S; Krbek T; Welter S; Grunenwald D; Fischer B; Rodrigo Hde L; Theegarten D; Le Chevalier T; Seeber S; Stuschke M; Poettgen C
Lung Cancer; 2013 Oct; 82(1):83-9. PubMed ID: 23957964
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.
Hainsworth JD; Gray JR; Litchy S; Bearden JD; Shaffer DW; Houston GA; Greco FA
Clin Lung Cancer; 2004 Jul; 6(1):33-42. PubMed ID: 15310415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]